School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino, 1, 62032, Camerino, MC, Italy.
ChemMedChem. 2016 Dec 6;11(23):2567-2574. doi: 10.1002/cmdc.201600453. Epub 2016 Nov 14.
The GPR17 receptor is a G protein-coupled receptor (GPCR) that seems to respond to two unrelated families of endogenous ligands: nucleotide sugars (UDP, UDP-galactose, and UDP-glucose) and cysteinyl leukotrienes (LTD , LTC , and LTE ), with significant affinity at micromolar and nanomolar concentrations, respectively. This receptor has a broad distribution at the level of the central nervous system (CNS) and is found in neurons and in a subset of oligodendrocyte precursor cells (OPCs). Unfortunately, disparate results emerging from different laboratories have resulted in a lack of clarity with regard to the role of GPR17-targeting ligands in OPC differentiation and in myelination. GPR17 is also highly expressed in organs typically undergoing ischemic damage and has various roles in specific phases of adaptations that follow a stroke. Under such conditions, GPR17 plays a crucial role; in fact, its inhibition decreases the progression of ischemic damage. This review summarizes some important features of this receptor that could be a novel therapeutic target for the treatment of demyelinating diseases and for repairing traumatic injury.
GPR17 受体是一种 G 蛋白偶联受体(GPCR),似乎对两类不相关的内源性配体有反应:核苷酸糖(UDP、UDP-半乳糖和 UDP-葡萄糖)和半胱氨酰白三烯(LTD、LTC 和 LTE),分别在微摩尔和纳摩尔浓度下具有显著的亲和力。该受体在中枢神经系统(CNS)水平具有广泛的分布,存在于神经元和少突胶质细胞前体细胞(OPC)的亚群中。不幸的是,不同实验室得出的不一致结果导致人们对 GPR17 靶向配体在 OPC 分化和髓鞘形成中的作用缺乏清晰的认识。GPR17 在通常发生缺血损伤的器官中也高度表达,并在中风后适应的特定阶段发挥各种作用。在这种情况下,GPR17 起着至关重要的作用;事实上,它的抑制作用会降低缺血损伤的进展。本综述总结了该受体的一些重要特征,它可能成为治疗脱髓鞘疾病和修复创伤的新的治疗靶点。